Navigation Links
Leukemia pill shows promise against stomach cancer

Gleevec, which was just approved for treating leukemia, also shows promise against a type of stomach cancer . The Food and Drug Administration approved the use of a promising anti-leukemia drug for treatment of a relatively rare form of abdominal cancer. The drug, Gleevec, administered as a pill once a day, is effective in treating both forms of cancer because of its ability to target and kill cancer cells without attacking healthy cells and causing severe side effects. //

Approved last spring for a common type of adult leukemia, Gleevec can now be used to treat gastrointestinal stromal tumors, or GIST, which affect as many as 5,000 people in the US each year. Studies have shown it to be as effective in treating chronic cases of GIST as it has been in treating chronic myelogenous leukemia (CML).

Researchers reported 59 percent of patients with advanced-stage GIST went into remission and up to 75 percent showed some type of improvement with limited side effects. GIST accounts for about two percent of all abdominal cancers. If caught early, these tumors can usually be removed surgically, but growths often return. According to its manufacturer, Novartis Oncology, Gleevec also is being studied as a possible treatment for prostate cancer, small-cell lung cancer and a rare type of brain cancer.
'"/>




Page: 1

Related medicine news :

1. Cyclosporin A Treats Leukemia Complications
2. Aspirin Lowers Leukemia Risk
3. Hope for Chemo-Resistant Leukemia Patients
4. Genes Found To Help Leukemia Treatment
5. Looking Towards More Effective Leukemia Treatment
6. Diet Found To Offer Protection Against Leukemia
7. Exposure To Night Light may Increase The Risk Of Leukemia
8. Skin Allergies Found To Increase The Risk Of Leukemia
9. Understanding Gene Profiles Could Help Cure A Resistant Form Of Leukemia In Kids
10. Night Light Found To Increase The Risk Of Leukemia
11. Treating Leukemia With Natural Cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2017)... ... 25, 2017 , ... CareSet Labs released the Root NPI Graph today at ... new, greatly improved version of the Doctor Referral teaming dataset commonly available from Medicare. ... subsequently called the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as ...
(Date:6/24/2017)... ... June 24, 2017 , ... The Pennsylvania Athletic Trainers’ ... Bayfront and Erie Convention Center on June 8-10. The weekend consisted of ... bowl, award and scholarship presentations, and professional networking. , On Friday June ...
(Date:6/23/2017)... ... 2017 , ... The Rhode Island Quality Institute (RIQI) and ... Dashboards, an innovative new service enabling healthcare providers to proactively coordinate care and ... Dashboards provide near real-time data about patients admitted to and/or discharged from acute ...
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that carotenoids ... risk of visual loss in these patients. , But how often do ophthalmologists and ... cessation to patients at risk of or with early symptoms of AMD? A ...
(Date:6/23/2017)... , ... June 23, 2017 , ... Everybody has their ... while others prefer to read it, and some people don't like it at all. ... Here's what they found: , Erotic literature can give readers a taste of their ...
Breaking Medicine News(10 mins):
(Date:5/26/2017)... SANTA BARBARA, Calif. , May 25, 2017 /PRNewswire-USNewswire/ ... the United States , Direct Relief is working ... of overdose-reversing Naloxone available at no cost to community ... and other nonprofit providers nationwide. "Pfizer ... expanding access to medicines and ensuring patient safety through ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, ... Gene-Eden-VIR/Novirin, announces the launch of a new ... the results of a clinical study that showed ... treatment with Gene-Eden-VIR/Novirin in individuals suffering from HPV ... note that there are no other treatments that ...
(Date:5/18/2017)... 17, 2017  Bayer announced today that the latest ... presented at the 53 rd Annual Meeting of ... June 2-6 in Chicago . ... prostate, colorectal, liver and thyroid cancers, as well as ... II CHRONOS-1 trial of copanlisib in patients with relapsed ...
Breaking Medicine Technology: